What Is Fibrillin and What Does It Do?

Fibrillin is a large glycoprotein that forms the structural backbone of tiny cable-like fibers, called microfibrils, threaded throughout your connective tissues. These microfibrils give stretch and resilience to blood vessels, skin, lungs, and the ligaments that hold your eye’s lens in place. But fibrillin does more than hold things together: it also acts as a control system for powerful growth-factor signals that tell cells when to grow, divide, or remodel their surroundings. When the gene encoding fibrillin is mutated, the consequences can range from the tall, lanky frame and dangerous aortic aneurysms of Marfan syndrome to rarer conditions involving stiff skin or shortened fingers.

The Three Fibrillins

Humans produce three forms of fibrillin, each encoded by its own gene. Fibrillin-1, encoded by the gene FBN1, is the most abundant and best studied. It is present in virtually every connective tissue from birth through adulthood and is the form most relevant to disease. Fibrillin-2, encoded by FBN2, is expressed primarily during fetal development and plays a key role in laying down the earliest elastic fiber scaffolds. Fibrillin-3, encoded by FBN3, was the last to be discovered and is the most mysterious. It shows up strongly in fetal tissues, including developing cartilage, skin, lung, kidney, and, unusually, the brain, where its function is still unclear.¹ Rodents have lost the FBN3 gene entirely, which is one reason it has been harder to study in animal models.

All three fibrillins share a common architecture: long, beaded chains built from repeating calcium-binding domains and a handful of unique modules that differ among the isoforms. In fibrillin-1, a proline-rich stretch sits near one end of the protein; in fibrillin-2, that same region is glycine-rich; and in fibrillin-3, it is a mix of both.² These differences matter because they influence which cells the protein talks to and how tightly it binds to neighboring molecules. Despite these distinctions, all three fibrillins are expressed in many of the same organs during early development, suggesting both overlapping and unique roles.³

How Fibrillin Builds Microfibrils

A single fibrillin molecule is huge by protein standards, but on its own it cannot do much. To become functional, many fibrillin molecules must link together into microfibrils, which are the thin, rope-like structures visible under an electron microscope with a characteristic “beads-on-a-string” appearance. The assembly process starts at the tail end (the C-terminus) of fibrillin-1, where several molecules cluster together through disulfide bonds to form dense globular structures resembling beads. Only after these bead-like multimers form can they reach out and connect with the head ends (N-termini) of neighboring multimers to extend the chain.⁴ Fibrillin-2 and fibrillin-3 follow a similar pattern, with their C-terminal halves also showing a tendency to multimerize.

This assembly does not happen in isolation. Fibrillin microfibrils depend on a pre-existing network of another matrix protein, fibronectin, to form properly. When fibronectin is absent, fibrillin assembly stalls. All three fibrillins interact strongly with fibronectin once they have formed their multimeric bead structures, but not as single molecules.⁵ Think of fibronectin as a scaffold that fibrillin needs in order to organize itself into the long filaments that ultimately give tissues their mechanical properties.

Giving Tissues Their Stretch

The most obvious job of fibrillin microfibrils is structural. They are found in the walls of large arteries, in skin, in the lungs, and in the suspensory ligaments of the eye, all places where tissues need to stretch and snap back repeatedly over a lifetime. Microfibrils give these tissues a form of limited, durable elasticity.⁶ They also serve as a template for elastin, the rubbery protein that provides the bulk of the recoil in elastic fibers. During development, elastin is deposited directly onto the microfibril scaffold, and the microfibrils remain embedded within the finished elastic fiber as a kind of internal reinforcement.

How much of the mechanical work microfibrils do on their own versus how much elastin carries is a question researchers have gone back and forth on. X-ray studies and biomechanical tests have shown that isolated microfibrils are reversibly extensible, stretching up to twice their resting length and bouncing back.⁷ Yet when researchers measured the stiffness of individual elastic fibers with and without microfibrils, the mechanical stiffness values were not significantly different, suggesting that in the context of a fully formed elastic fiber, microfibrils are not the primary load-bearing component.⁸

That does not mean the microfibrils are mechanically irrelevant in living tissue. In the pig aorta, removing microfibrils changed how force was distributed among the elastin fibers, reducing stiffness at low strains and increasing it at high strains. The interpretation is that microfibrils help redirect and share mechanical load across neighboring elastin fibers, keeping the arterial wall from overstretching in any one spot.⁹ In the eye, the suspensory ligaments (zonules) that hold the lens in focus are almost entirely fibrillin-based, with very little elastin. When fibrillin-1 production was knocked out specifically in the eye of mice, the zonule fibers became thinner and weaker, and by three months the fibers ruptured, causing the lens to dislocate, a hallmark of Marfan syndrome.¹⁰

Controlling Growth Factor Signals

Perhaps the most surprising thing about fibrillin is that it moonlights as a signal regulator. The extracellular matrix is not just passive scaffolding; it stores inactive growth factors and releases them at the right time and place. Fibrillin microfibrils are central to this storage system for at least two families of signaling molecules: TGF-β (transforming growth factor beta) and BMPs (bone morphogenetic proteins).

TGF-β is secreted in a latent form, wrapped in a straitjacket of proteins that keep it inactive. Those wrapper proteins, called LTBPs (latent TGF-β binding proteins), physically attach to fibrillin microfibrils to park the whole complex in the matrix until a signal triggers its release.¹¹ Two of the four LTBP isoforms, LTBP-3 and LTBP-4, depend specifically on fibrillin-1 microfibrils to get incorporated into the matrix at all. In mice lacking fibrillin-1, those two LTBPs simply fail to deposit, while LTBP-1 can still anchor itself to fibronectin instead.¹² The practical result: when fibrillin-1 is defective, TGF-β signaling becomes dysregulated, and that excess signaling drives much of the tissue damage seen in Marfan syndrome.

Fibrillin plays an analogous role for BMPs, except here binding to fibrillin can actually impose latency. When the BMP-7 complex attaches to fibrillin-1, it is forced into a closed ring shape that prevents BMP receptors on nearby cells from accessing the growth factor.¹³ In other words, fibrillin does not just store BMPs; it actively shuts them off until the appropriate release signal arrives. This puts fibrillin microfibrils at a crossroads of signaling, simultaneously dampening some growth-factor pathways while keeping them ready for rapid activation.

Talking to Cells Through Integrins

Fibrillin is not just a passive partner that cells build and forget about. It carries a short amino acid sequence, RGD, that functions as a docking site for integrins, the receptor proteins on the cell surface that anchor cells to the matrix and relay signals inward. In fibrillin-1, this RGD site sits in a specific domain and is evolutionarily conserved across species, pointing to its functional importance.¹⁴ Through this site, fibrillin-1 can trigger changes in gene expression inside cells, including regulation of small RNA molecules that fine-tune which proteins the cell makes.

In endothelial cells, the cells lining blood vessels, fragments of fibrillin-1 containing this integrin-binding region boosted calcium signaling, cell division, and cell migration.¹⁵ This suggests that fibrillin is not merely structural or a passive growth-factor warehouse; it is actively telling nearby cells what to do. When the RGD site is disrupted by mutation, the results are dramatic. Mutations in this single domain cause stiff skin syndrome, a rare congenital condition where excessive microfibril deposition, failed elastic fiber formation, and overactive TGF-β signaling combine to produce thick, rigid skin that limits movement from birth.¹⁶

Marfan Syndrome and Other Fibrillinopathies

The most well-known consequence of fibrillin gone wrong is Marfan syndrome, caused by mutations in FBN1. Over a thousand individual FBN1 mutations have been identified in affected families, which partly explains why the condition varies so much from person to person.¹⁷ The classic features include a tall, lean build with unusually long fingers, lens dislocation in the eye, and progressive widening of the aortic root, the section of the aorta closest to the heart. The aortic involvement is the most dangerous feature, because an aorta that has lost its microfibril scaffolding can eventually tear or rupture.

It was once assumed that the structural weakness itself was the whole problem, as if removing threads from a rope simply made it weaker. That picture changed when researchers discovered that excessive TGF-β signaling, unleashed by faulty fibrillin-1, drives much of the progressive tissue damage in the aortic wall.¹⁸ Aortic tissue from Marfan patients shows elevated TGF-β activity and increased levels of enzymes that chew up the extracellular matrix, compounding the structural deficit.¹⁹ Understanding this signaling dimension transformed treatment strategies.

Mutations in FBN2 cause a different condition, Beals syndrome (congenital contractural arachnodactyly), which shares some features with Marfan syndrome, like long fingers and ear abnormalities, but primarily involves joint contractures and curvature of the spine rather than aortic disease.²⁰ Intriguingly, mutations in specific regions of FBN1 can produce the opposite of the Marfan body type: short stature and short, broad fingers, features of Weill-Marchesani syndrome and related conditions. The fact that different mutations in the same gene can produce near-opposite physical traits underscores how sensitive tissue development is to the precise behavior of fibrillin microfibrils in different locations.¹⁷

Treatment Strategies Targeting TGF-β

The discovery that runaway TGF-β signaling contributes to aortic disease in Marfan syndrome opened the door to drug-based treatments, a significant shift for a condition that had previously been managed almost entirely through surveillance and surgery. Beta-blockers have long been the standard medication to slow aortic growth by reducing blood pressure and the force of each heartbeat, but they do not address the signaling problem directly.

Losartan, a common blood-pressure drug, attracted attention because it can dampen TGF-β activity in addition to lowering blood pressure. Early results in mouse models were encouraging, and clinical trials in humans followed. A Dutch trial found that losartan reduced the rate of aortic widening in Marfan patients, though a closer look suggested the benefit was mainly in patients whose specific FBN1 mutation led to reduced fibrillin-1 production rather than production of a defective protein that poisons the microfibril. A separate French trial found that losartan lowered blood pressure but did not significantly slow aortic growth when added on top of beta-blockers.²¹ The mixed results point to how much the specific type of FBN1 mutation matters and why genotype-phenotype correlations remain difficult. Even so, these trials represented the first pharmacological interventions targeting the molecular biology of a connective tissue disorder, rather than simply managing its downstream effects.²²

Fibrillin and Skin Aging

If you have ever wondered why sun-exposed skin loses its elasticity faster than skin that stays covered, fibrillin is part of the answer. Loss of fibrillin microfibrils in the upper layers of skin is one of the earliest markers of sun damage, appearing before the more visible changes like deep wrinkling. Researchers have shown that fibrillin microfibrils are directly degraded by UV-B radiation at doses you might actually encounter outdoors.²³ The elastic fiber proteins in general are unusually rich in amino acids that absorb UV light, which may explain why they are particularly vulnerable to photodamage.

The damage is a two-hit process. UV exposure first creates reactive oxygen species that alter the structure of fibrillin microfibrils. On their own, the enzymes that normally remodel the matrix (matrix metalloproteinases, or MMPs) have relatively little effect on healthy microfibrils. But once UV has pre-damaged the fibrillin, those same enzymes can selectively chew up the altered structures.²⁴ This helps explain why chronic sun exposure leads to cumulative, irreversible loss of skin elasticity: each round of UV exposure primes more microfibrils for destruction, and the cleanup enzymes, upregulated by the UV itself, finish the job.

Fibrillin-3 and Fetal Development

While fibrillin-1 dominates in adult tissues, fibrillin-3 occupies an odd niche. Its expression peaks during the first trimester in human embryos, appearing in developing cartilage, skin, airways, kidneys, and the heart, and then largely fades after birth.³ One intriguing finding is that fibrillin-3 shows strong expression in the fetal brain, unlike fibrillin-1 or fibrillin-2, hinting at a role in nervous system development that has not been fully explored.¹

A separate line of research has drawn a connection between fibrillin-3 and the early fetal ovary. Prominent, transient fibrillin-3 expression has been found in the ovarian stroma during early gestation in both humans and cattle. Because the FBN3 gene lies near genomic regions linked to polycystic ovary syndrome (PCOS), some researchers have speculated that fetal-stage fibrillin-3 could influence the developmental origins of PCOS, though this remains an early hypothesis rather than an established mechanism.²⁵

Fibrillin in Cancer Biology

Research into fibrillin has begun to extend beyond connective tissue diseases and into cancer. The tumor microenvironment, the web of matrix proteins and signals surrounding a tumor, plays a significant role in whether cancer cells stay put or migrate to other parts of the body. Fibrillin-1 has been found to promote metastasis in ovarian cancer. In laboratory and animal experiments, fibrillin-1 suppressed cell-adhesion molecules that normally keep cells anchored in place and activated enzymes that break down surrounding matrix, effectively paving the way for tumor cells to invade neighboring tissues. Animal studies showed that fibrillin-1 promoted both tumor growth and metastatic spread in ovarian cancer models.²⁶ This is still an active and early area of investigation, but it reinforces the idea that fibrillin’s signaling functions have wide-reaching biological consequences well beyond tissue elasticity.

An Ancient Protein Family

Fibrillins are not a recent evolutionary invention. They are found across vertebrates and have now been identified in insects as well, though with significant structural divergence. Among insect fibrillins, only the group annotated as fibrillin-2 homologs shares the hallmark domain architecture and sequence features of vertebrate fibrillins, suggesting that this form branched off early from a shared ancestral protein.²⁷ The conservation of the core fibrillin structure across such distantly related animals suggests that the microfibril system was already performing essential mechanical and signaling work hundreds of millions of years ago, long before the complex elastic tissues of modern mammals evolved.